Soligenix 경영진

경영진 기준 점검 2/4

Soligenix CEO는 Christopher Schaber, Aug2006 에 임명되었습니다 의 임기는 19.5 년입니다. 총 연간 보상은 $832.63K, 64.9% 급여 및 35.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $17.22K 가치에 해당하는 회사 주식의 0.15% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 11.6 년과 16.3 년입니다.

핵심 정보

Christopher Schaber

최고경영자

US$832.6k

총 보수

CEO 급여 비율	64.89%
CEO 재임 기간	19.5yrs
CEO 지분 보유율	0.2%
경영진 평균 재임 기간	11.6yrs
이사회 평균 재임 기간	16.3yrs

최근 경영진 업데이트

Recent updates

Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely

Aug 20

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

CEO 보수 분석

Christopher Schaber의 보수는 Soligenix의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Sep 30 2025	n/a	n/a	-US$11m
Jun 30 2025	n/a	n/a	-US$10m
Mar 31 2025	n/a	n/a	-US$10m
Dec 31 2024	US$833k	US$540k	-US$8m
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$700k	US$519k	-US$6m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m

보상 대 시장: Christopher의 총 보수(USD832.63K)는 US 시장에서 비슷한 규모 기업의 평균(USD575.81K)보다 높습니다.

보상과 수익: Christopher의 보상은 회사가 적자임에도 증가했습니다.

CEO

Christopher Schaber (59 yo)

19.5yrs

재임 기간

US$832,626

보수

Dr. Christopher J. Schaber, Ph D., is Trustee of BioNJ Inc. Dr. Schaber was Trustee of BioNJ Inc. until February 2019. Dr. Schaber has been the President and Chief Executive Officer at Soligenix, Inc. sinc...

리더십 팀

이름	직위	재임 기간	보수	지분
Christopher Schaber	Chairman of the Board of Directors	19.5yrs	US$832.63k	0.15% $ 17.2k
Jonathan Guarino	Senior VP	6.4yrs	US$399.18k	0.00046% $ 51.5
Oreola Donini	Senior VP & Chief Scientific Officer	11.2yrs	US$432.11k	0% $ 0
Richard Straube	Consultant	12.1yrs	US$268.68k	0.00034% $ 38.1

11.6yrs

평균 재임 기간

56yo

평균 나이

경험이 풍부한 관리: SNGX의 경영진은 노련하고 경험이 풍부합니다(평균 재임 11.6 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Christopher Schaber	Chairman of the Board of Directors	19.5yrs	US$832.63k	0.15% $ 17.2k
Jerome Zeldis	Independent Director	14.7yrs	US$80.00k	0.00095% $ 106.4
Gregory Lapointe	Independent Director	16.9yrs	US$85.00k	0.00031% $ 34.7
Robert Rubin	Independent Director	16.3yrs	US$87.50k	0.00019% $ 21.3
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	데이터 없음	데이터 없음
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	데이터 없음	데이터 없음
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	데이터 없음	데이터 없음
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	데이터 없음	데이터 없음
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	데이터 없음	데이터 없음
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	데이터 없음	데이터 없음
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	데이터 없음	데이터 없음
Brian Poligone	Chair of Cutaneous T-Cell Lymphoma Medical Advisory Board	less than a year	데이터 없음	데이터 없음

16.3yrs

평균 재임 기간

70.5yo

평균 나이

경험이 풍부한 이사회: SNGX의 이사회는 노련하고 경험이 풍부합니다(평균 재임 16.3 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/02/20 01:50
종가	2026/02/20 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 우리의 Github 페이지에서 확인하실 수 있으며, 보고서를 활용하는 방법에 대한 가이드와 유튜브 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Soligenix, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
James Molloy	Alliance Global Partners
Andrew D'Silva	B. Riley Securities, Inc.
Keith Markey	Griffin Securities

Soligenix 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, Jun 20, 2025

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Insufficient new directors

Recent updates

New major risk - Revenue and earnings growth

Soligenix, Inc. has filed a Follow-on Equity Offering in the amount of $3.45 million.

Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford)

Soligenix Inc. Announces Audio Press Release on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte™? for the Treatment of Cutaneous T-Cell Lymphoma

New major risk - Financial position

Soligenix Achieves Important Safety Milestone in Its Confirmatory Phase 3 Clinical Trial of Hybryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc. has completed a Follow-on Equity Offering in the amount of $7.500006 million.

New major risk - Market cap size

Soligenix, Inc. has filed a Follow-on Equity Offering in the amount of $7.999998 million.

Soligenix, Inc. Announces Publication Recommending Long-Term High Temperature Stability of Protein Subunit Vaccines forbola and Related Viruses

Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely

Soligenix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for its Common Stock

Soligenix Inc. Announces Audio Press Release on Promising First-Line Therapy for Rare Skin Cancer

New major risk - Share price stability

Soligenix, Inc. Completes its Phase 2a Proof of Concept Study Evaluating SGX945 (Dusquetide) in Treatment of Behcet's Disease and Achieves Study Objective of Demonstrating Biological Efficacy

Soligenix, Inc. Announces Synthetic Hypericin Successfully Manufactured At Sterling Pharma Solutions

Soligenix, Inc. Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte in Ongoing Clinical Trials

First quarter 2025 earnings released: US$1.06 loss per share (vs US$2.91 loss in 1Q 2024)

Soligenix, Inc., Annual General Meeting, Jun 20, 2025

Soligenix, Inc. Announces Interim Results from the Ongoing Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

No longer forecast to breakeven

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte

Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 13% to US$35.00

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 29% to US$2.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Consensus EPS estimates upgraded to US$0.63 loss

Price target increased by 7.7% to US$3.50

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Consensus revenue estimates decrease by 11%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

New major risk - Share price stability

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 35% to US$3.25

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Consensus revenue estimates increase by 13%

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors